NSE: NATCOPHARM | BSE: 524816

Mid-range Performer

Download real time

929.65 14.80 (1.62%)

37.61% Fall from 52W High

462.0K NSE+BSE Volume

NSE 19 Dec, 2025 10:37 AM (IST)

16,651

Market Cap

High in industry

Beta 1Year

Very High Volatility

Natco Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for NATCOPHARM, BSE:524816 Natco Pharma Ltd.

Natco Pharma Ltd.

13 Aug 2022

929.65

1.62%

Natco Pharma Limited

Hold: Natco Pharma Ltd.

Target

ICICI Direct

Natco Pharma has lost -35.70% in the last 1 Year

Natco Pharma Ltd.

11 Aug 2022

929.65

1.62%

Revlimid leads Q1FY23 performance

Buy: Natco Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Natco Pharma’s (Natco) Q1FY23 performance was ahead of our estimates led by ramp-up in Revlimid.

Number of MF schemes decreased from 47 to 19 in Sep 2025 qtr

Natco Pharma Ltd.

01 Jun 2022

929.65

1.62%

Natco Pharma Limited

Hold: Natco Pharma Ltd.

ICICI Direct

Number of FII/FPI investors decreased from 317 to 235 in Sep 2025 qtr

Natco Pharma Ltd.

18 Feb 2022, 12:00AM

929.65

1.62%

Natco Pharma Limited

Hold: Natco Pharma Ltd.

Target

ICICI Securities Limited

...

Number of MF schemes decreased from 47 to 19 in Sep 2025 qtr

Natco Pharma Ltd.

14 Nov 2021

929.65

1.62%

Natco Pharma Limited

Hold: Natco Pharma Ltd.

Target

ICICI Securities Limited

40x P/E on FY23E EPS + | 119 NPV for gRevlimid) Key triggers for future price performance: Expected momentum for H2FY22 is likely due to some high profile launches...

Natco Pharma Ltd. is trading above all available SMAs

Natco Pharma Ltd.

27 Aug 2021

929.65

1.62%

NATCO PHARMA

Hold: Natco Pharma Ltd.

Target

Geojit BNP Paribas

recovery in the domestic business front but registered a 27% YoY degrowth due to a higher base in Q1FY21 attributable to covid sales. The company reported strong growth in domestic business with a strong position in oncology and hepatitis-c domains. APIs registered a decline of 57% YoY and export formulations de-grew 47% YoY to 145cr. Resultantly, EBITDA margins contracted 300bps YoY to 27% and EBITDA declined 35.8% YoY to Rs.109.8cr. With approval in both Hyderabad and Vizag facilities, Revlimid is expected to be launched in the March quarter of FY22. In the agro-chemical business front, the company has launched...

Number of FII/FPI investors decreased from 317 to 235 in Sep 2025 qtr

Natco Pharma Ltd.

13 Aug 2021

929.65

1.62%

Natco Pharma Limited

Hold: Natco Pharma Ltd.

Target

ICICI Securities Limited

What should investors do? Natco's share price has grown by ~1.6x over the past five years (from ~| 632 in July 2016 to ~| 1024 levels in July 2021). We retain our HOLD rating on this stock...

Natco Pharma Ltd. has an average target of 845.00 from 2 brokers.

Natco Pharma Ltd.

24 Jun 2021

929.65

1.62%

NATCO PHARMA

hold: Natco Pharma Ltd.

Target

Geojit BNP Paribas

Molnupiravir for the treatment of Covid-19 patients. New launches in the Indian market are expected to drive domestic earnings with ~10 new product launches a year. The company has forayed into the agro-chemical business and invested in the Crop Health Sciences Division targeting niche products. Natco received final approval for Revlimed (Lenalidomide capsules) and...

Number of FII/FPI investors decreased from 317 to 235 in Sep 2025 qtr

Natco Pharma Ltd.

18 Jun 2021, 12:00AM

929.65

1.62%

Natco Pharma Limited

Hold: Natco Pharma Ltd.

Target

ICICI Securities Limited

Natco is a leading player in the domestic oncology segment with a product basket of ~33 products (FY20). Covid related disturbances and pricing pressure notwithstanding, we expect momentum in oncology segment to be decent on the back of incremental launches. New launches in cardio/diabetology segment (CND) is also expected to support overall growth. Going ahead, Natco is looking to launch 10 products a year. We...

Natco Pharma Ltd. has an average target of 845.00 from 2 brokers.

Natco Pharma Ltd.

01 Jun 2021

929.65

1.62%

Ashika - Stock Picks - Natco Pharma Ltd. - June 2021

Buy: Natco Pharma Ltd.

Target

Ashika Research

Natco Pharma Ltd. (NPL) is a midsized pharmaceutical company with a presence across the pharma value chain. It owns eight manufacturing facilities including six formulations facilities and two API facilities. The company also has a US retail business. Natco is a leading domestic player in the oncology space. NPL's product pipeline consists of drugs,...

Number of FII/FPI investors decreased from 317 to 235 in Sep 2025 qtr

Is Natco Pharma Ltd. worth buying?

594 Votes:

Buy 83.0%

Sell 7.41%

Hold 9.6%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf